P-Akt expression distinguishes two types of malignant rhabdoid tumors
Article first published online: 8 AUG 2006
Copyright © 2006 Wiley-Liss, Inc.
Journal of Cellular Physiology
Volume 209, Issue 2, pages 422–427, November 2006
How to Cite
Charboneau, A., Chai, J., Jordan, J., Funkhouser, W., Judkins, A., Biegel, J. and Weissman, B. (2006), P-Akt expression distinguishes two types of malignant rhabdoid tumors. J. Cell. Physiol., 209: 422–427. doi: 10.1002/jcp.20737
- Issue published online: 29 AUG 2006
- Article first published online: 8 AUG 2006
- Manuscript Accepted: 12 JUN 2006
- Manuscript Received: 18 MAY 2006
- American Brain Tumor Association Chad Dunbar Postdoctoral Fellowship
- PHS. Grant Number: CAT3209156
- PHS. Grant Number: CA91048
- PHS. Grant Number: CA46274
Highly aggressive pediatric malignant rhabdoid tumors (MRT) arise in the kidney and central nervous system (CNS) with no curative treatment available. Multiple studies have shown that inactivation of the SNF5 tumor suppressor gene occurs in virtually all MRTs. However, few studies have addressed whether additional genetic events may contribute to MRT development. In this report, we demonstrate that phosphorylated Akt (P-Akt) is expressed in a subpopulation of cells in at least 10% of primary rhabdoid tumors as well as at high levels in three MRT cell lines. Similar to other high P-Akt expressing tumor cell lines, MRTs have decreased sensitivity to p21 induced growth arrest. Therefore, P-Akt expression may distinguish between two types of MRTs. Because drugs directed against the PI3-K/Akt have shown promise in clinical trials for other tumor types, they may prove useful for treatment of patients with P-Akt positive MRTs. P-Akt expression also provides a potential mechanistic link between these pediatric tumors and adult malignancies. J. Cell. Physiol. 209: 422–427, 2006. © 2006 Wiley-Liss, Inc.